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A cornerstone of the global initiative to eradicate polio is the widespread use of live and inactivated poliovirus vaccines in extensive
public health campaigns designed to prevent the development of paralytic disease and interrupt transmission of the virus. Central
to these efforts is the goal of inducing mucosal immunity able to limit virus replication in the intestine. Recent clinical trials have
evaluated new combined regimens of poliovirus vaccines, and demonstrated clear differences in their ability to restrict virus
shedding in stool after oral challenge with live virus. Analyses of mucosal immunity accompanying these trials support a critical role
for enteric neutralizing IgA in limiting the magnitude and duration of virus shedding. This review summarizes key findings in
vaccine-induced intestinal immunity to poliovirus in infants, older children, and adults. The impact of immunization on
development and maintenance of protective immunity to poliovirus and the implications for global eradication are discussed.
Mucosal Immunology; https://doi.org/10.1038/s41385-021-00428-0
INTRODUCTION
Successful implementation of the polio endgame will depend on
immunization strategies that not only prevent paralytic disease, but
also limit enteric replication of the virus and minimize the risk of
transmission of potentially neurovirulent strains1–4. Vaccines contain-
ing live attenuated poliovirus have been the mainstay of immuniza-
tion campaigns for decades, and remain a critical component of
efforts to eradicate wild-type virus5. Oral polio vaccine (OPV) replicates
extensively in the gastrointestinal tract and is distinguished by its
ability to induce intestinal immunity, and decrease virus shedding
upon subsequent exposure of individuals to live virus6. In contrast,
inactivated polio vaccine (IPV), while inducing strong systemic
immunity and protection from paralytic disease, has little effect on
virus replication in the intestine following an OPV challenge in
subjects previously not exposed to live virus7.
Concerns over the safety of OPV due to rare cases of vaccine-
associated paralytic polio (VAPP) caused primarily by the type 2
component of the vaccine, and the introduction of vaccine-
derived polioviruses (VDPV) into areas of low population
immunity, led to the removal of the type 2 component from
trivalent OPV (tOPV) and a globally synchronized switch from tOPV
to bOPV (types 1 and 3) in 20168. Coupled with this change was
the recommendation to include at least one dose of IPV in
immunization strategies to prime individuals against potential
exposure to type 2 poliovirus, and to boost population immunity
against all three serotypes3.
Vaccination regimens consisting of IPV, bOPV, and combina-
tions thereof have since been evaluated in clinical trials to assess
rates of seroconversion and virus shedding in response to a
monovalent OPV (mOPV) challenge9–15. These trials revealed a
marked difference in the degree of protection induced by tOPV
versus bOPV and IPV against strain-specific enteric poliovirus
replication as measured by recovery of type 2 virus in stool. To
gain insight into the ability of combined bOPV and IPV regimens
to induce intestinal immunity, mucosal antibody responses have
been studied within the context of these trials15–18. Consistent
with early observations, these studies demonstrate an important
role for neutralizing antibody responses mediated by IgA in
limiting replication of poliovirus in the intestine 6,19–23.
This review summarizes current findings in mucosal immunity
to poliovirus and provides a theoretical framework for interpreting
observed differences in vaccine-induced intestinal immunity to
bOPV and IPV regimens across age groups. The broader
implications for the prevention of poliovirus infection and
transmission within global eradication efforts are discussed.
MUCOSAL IMMUNITY TO LIVE AND INACTIVATED POLIOVIRUS
VACCINES IN INFANTS
Combined OPV and IPV as a primary series
Recommendations to assess combined OPV and IPV schedules in
infants were first presented in 1987 by the Global Advisory Group
of the WHO Expanded Program on Immunization24. An over-
arching goal for combined vaccine use was to improve early
protection against polio and strengthen immunity in children from
developing countries, where OPV-only schedules were associated
with lower than expected rates of seroconversion25–29. Combining
OPV and IPV to broaden immunogenicity to poliovirus was
subsequently evaluated in a clinical trial of 1685 infants from The
Gambia, Oman, and Thailand30. A seminal finding from this study
was that IPV alone failed to provide adequate protection from
poliovirus shedding, while the combined regimen of OPV with IPV
induced strong seroconversion and intestinal immunity as
measured by a reduction in virus excreted in stool.
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Results from this and subsequent clinical trials31–37 formed the
cornerstone of current efforts to evaluate the effectiveness of
combined vaccine regimens in infants using new schedules of
bOPV and IPV9–15. A central objective of these trials is to define the
best strategy not only for preventing paralytic disease, but also for
inducing intestinal immunity and limiting virus shedding. Using
updated immunological techniques to measure polio-specific
enteric antibody responses, further studies have linked the
induction of intestinal immunity to the type and timing of the
primary vaccine series16–18. When evaluated alongside concurrent
data on virus shedding, these immunologic analyses have allowed
a more nuanced picture to emerge of the induction and
development of enteric antibody responses to bOPV and IPV
regimens, and the relationship of these responses to virus
shedding upon subsequent challenge with mOPV.
Comparative studies of intestinal immunity to combined
vaccine schedules
Initial studies examined the induction of intestinal immunity to
bOPV and IPV-containing regimens in comparison to the “gold
standard” of a tOPV regimen. Infants from Latin American
countries within the FIDEC (Fighting Infectious Diseases in
Emerging Countries) consortium were studied to evaluate the
immunogenicity of tOPV in comparison to two schedules of bOPV
and IPV13 (Fig. 1). Not unexpectedly, robust intestinal IgA and
strain-specific neutralizing responses were found in infants
exposed to live poliovirus as a tOPV primary series16. These
responses were evident on the day of challenge and corre-
sponded to a marked restriction in type-specific virus shedding
after oral exposure to mOPV216.
In comparison, infants receiving a bOPV or bOPV–IPV series had
negligible polio type 2-specific enteric antibody on the day of
challenge. Significant type 2-specific IgA and neutralizing activity
developed only after challenge with mOPV2 and reached peak
levels comparable to those in the tOPV group by 2 weeks16.
Addition of IPV to the bOPV series had no significant effect on
virus shedding after challenge as compared with bOPV only
schedules16. These results point to a restriction of type-specific
virus shedding that is clearly associated with prior receipt of
homotypic live virus (tOPV), and are consistent with early
observations that induction of mucosal immunity to poliovirus
in the intestine is stimulated by enteric replication of the virus19,38.
Further, these results demonstrate the limited impact of a single
dose of IPV when added after bOPV in a primary series to reduce
fecal shedding following oral exposure to live poliovirus.
Contribution of inactivated poliovirus vaccine to intestinal
immunity
The impact of IPV on induction of intestinal immunity and efforts to
elucidate the contribution of IPV in combined schedules with bOPV
have been evaluated in clinical trials; however, these results can be
confounded by prior receipt of live vaccine or by environmental
exposures to OPV-related polioviruses30,39,40. A 2015 clinical trial
conducted in Chile examined the immunogenicity of an IPV-only
primary series, in comparison to IPV-bOPV schedules, in infants for
whom there was no prior polio vaccine exposure11 (Fig. 1). High rates
of seroconversion were found for infants receiving an IPV or IPV+
bOPV series, yet further analysis showed only minimal enteric
antibody responses prior to challenge in infants receiving the IPV-
only series17. Challenge with mOPV2 induced a rapid intestinal
antibody response in the IPV-immunized infants, characterized by a
significant increase in polio type-specific IgA and virus neutralizing
activity in stool 2 weeks after oral exposure to live virus. These
findings again reinforce the concept that induction of type-specific
enteric antibody to poliovirus in infants is stimulated by replication of
live virus in the intestine. Moreover, in vaccine-naïve subjects, receipt
of an IPV-only primary series is insufficient to induce significant levels
of enteric IgA and virus neutralizing activity in the absence of OPV.
The conclusion that a primary IPV-only series does not induce
sufficient intestinal immunity to reduce fecal excretion of
Fig. 1 Global clinical trials of poliovirus vaccines in infants, children and adults. Clinical trials were conducted to assess induction of polio
type-specific immunity in response to immunization and OPV challenge in infants (FIDEC, Chile, Panama)11–13, children (Lithuania)51, and adults
(Sweden, Belgium)54,56. Induction of polio type-specific intestinal immunity for each trial was evaluated in a related set of studies16–18,51,55,57.
Details of the primary immunization schedules and type-specific OPV challenges for each study are published and briefly summarized here.
FIDEC (Fighting Infectious Diseases in Emerging Countries): Infants were randomized to receive a primary series of tOPV-tOPV-tOPV, bOPV-
bOPV-bOPV or bOPV-bOPV-bOPV+IPV at 6, 10, and 14 weeks of age, followed by mOPV2 challenge at 18 weeks13. Chile: Infants were
randomized to receive IPV-IPV-IPV, IPV-IPV-bOPV, or IPV-bOPV-bOPV at 8, 16, and 24 weeks of age, followed by mOPV2 challenge at 28 weeks11.
Panama: Infants received bOPV at 6, 10, and 14 weeks of age and were randomized to receive a standard dose of IPV or a monovalent high-
dose type 2-specific IPV (mIPV2HD) at 14 weeks, followed by mOPV2 at 18 weeks12. Lithuania: Children (ages 1–5 years) who had received 3–4
doses of IPV at 2, 4, 6, and 18 months of age were challenged with a dose of mOPV2 at study entry. A second dose of mOPV2 was given 28 days
after the first in a subset of the children51. Sweden: Adults who had received 3–4 doses of IPV in childhood were challenged at study entry with
mOPV154. Belgium: Adults who had received up to six doses of IPV in childhood were challenged with a single dose of nOPV2 at study entry56.















poliovirus after oral live-virus challenge is consistent with evidence
from several early studies7,19,41, and further aligns with a 2012
meta-review demonstrating the limited impact of IPV on fecal
shedding within one month after challenge with live virus42. In
light of these findings, our current understanding of the capacity
of IPV to elicit mucosal immunity capable of reducing virus
replication in the intestine, and the nature of the vaccine series
needed to achieve this goal, remain uncertain43.
Boosting intestinal immunity after priming with OPV
While it is clear that at standard doses IPV alone fails to stimulate
mucosal antibody responses in the intestine, increases in mucosal
immunity have been noted in studies in which a single dose of IPV
was given to individuals previously primed by OPV7,31,43–45. The
mechanism by which IPV boosts intestinal immunity in this
context is not well understood but presumably reflects reactiva-
tion of polio-specific memory responses established during initial
enteric exposure to live virus7. The magnitude of the boosting
effect of IPV on OPV-primed intestinal immunity is most evident in
older children and young adults, as compared to infants, and likely
reflects waning of the intestinal response in the intervening period
between oral exposure to live virus and the IPV boost7,31,43,45.
This finding raises questions as to whether the boosting effect
of IPV on mucosal immunity might be enhanced in a primary
series by increasing the dose of inactivated vaccine given in
combined regimens with bOPV. A recent clinical trial conducted in
Panama examined the gain, if any, in primary intestinal
immunogenicity in infants receiving bOPV and either a standard
dose of IPV or a novel monovalent high-dose type 2-specific IPV
(mIPV2HD)12 (Fig. 1). Significantly higher rates of seroconversion
and higher type-specific serum titers were associated with
mIPV2HD as compared to standard IPV suggesting that increasing
the dose of IPV may be effective for enhancing polio-specific
serum antibody responses12.
In comparison, no clear benefit was found for high-dose IPV in
stimulating intestinal immunity18. Polio type-specific enteric IgA
and neutralizing responses developed similarly in both vaccine
groups within 2 weeks of mOPV2 challenge and restriction of virus
shedding was not substantively changed in infants receiving
mIPV2HD as compared to standard IPV18. These findings under-
score the distinction in immunological responses to IPV between
the serum and mucosal compartments19, and further suggest
these differences may not be effectively overcome by increasing
the dose of IPV used in a primary schedule with bOPV.
Taken together these studies provide compelling evidence that
enhancing serum neutralization through the addition of standard,
or high-dose IPV to a primary bOPV immunization series does not
yield a comparable gain in intestinal immunity upon subsequent
exposure to live type 2 poliovirus. Moreover, these findings
support prior observations that polio-specific enteric immunity is
distinct from the serum response and is a primary determinant of
virus shedding6,19,23.
Further insight into the intestinal antibody response emerged
from the Panamanian study, which assessed polio type-specific
IgA1, IgA2, IgG, IgD, and IgM levels in stool relative to virus
neutralization and shedding following mOPV2 challenge18. While
poliovirus type 2-specific IgD was inversely associated with viral
shedding at 1 week after challenge, this response waned by
2 weeks and a stronger inverse correlation emerged between virus
shedding and type 2-specific IgA. Among subjects shedding virus,
levels of type 2-specific IgA1 correlated more strongly than IgA2
with both total IgA and stool neutralization, indicating that IgA1
may be the predominant isotype mediating mucosal neutraliza-
tion of poliovirus in the intestine.
Collectively, this series of clinical and immunologic studies in Latin
American infants demonstrates induction of polio type-specific enteric
IgA and virus neutralizing activity on mOPV2 challenge in infants
receiving either bOPV or bOPV–IPV as a primary series. A highly
significant inverse correlation was found between the enteric mucosal
responses and the amount of virus shed after challenge16–18. A central
message emerging from these trials in infants is that prior live vaccine
(tOPV or bOPV) induces strain-specific intestinal immunity and
effectively limits virus replication on oral challenge16. Further addition
of IPV (either standard or high dose) to a bOPV primary series has
limited impact on the induction of enteric antibodies or virus
shedding. This observation falls within the scope of a recent meta-
analysis of serum and mucosal responses to different poliovirus
vaccine regimens, which found no evidence of increased intestinal
immunity to type 2 virus associated with the addition of IPV to a
bOPV schedule46.
MUCOSAL IMMUNITY IN OLDER CHILDREN AND ADULTS
Waning of vaccine-induced intestinal immunity to poliovirus
Fewer studies have examined mucosal immunity to poliovirus in
older children and adults for whom the interval between the
primary vaccine series and subsequent exposure to live virus may
be considerably longer. Analyses of fecal IgA responses in older
children show poor responses among those immunized with OPV
in infancy, and challenged with live virus 9 years later as compared
to infants vaccinated with OPV twice within an interval of
6 weeks47. The observation that revaccination with OPV after an
extended period is associated with immunologic boosting
supports the concept that intestinal immunity wanes over
time47,48. Indeed, studies by Grassly and colleagues have shown
that protection against virus replication in children receiving OPV
partially wanes within a year of initial vaccination, and may be
incomplete even after multiple vaccine doses49.
That intestinal immunity to poliovirus diminishes with age is
supported by age-related studies in older children (1–4 years)
showing that the odds of virus excretion increase significantly with
the time since last vaccine exposure49. Studies by Jafari et al.44
show that fecal shedding of poliovirus in children with prior IPV
occurs in a significantly higher proportion of older children (10
years of age) as compared to those 6 and 11 months at the time of
bOPV challenge. Persistent virus shedding on OPV challenge has
also been shown in an early study of adolescent volunteers with
prior exposure to IPV or OPV in childhood50. Efforts at boosting
intestinal immunity with a single dose of IPV appear to be more
effective in children primed with OPV on average 7 months prior to
the IPV boost31 as compared to serial administration of OPV and
IPV as a primary series16,18,30,33, providing further evidence that
intestinal immunity wanes after primary immunization and may be
boosted by a subsequent later exposure to IPV31.
Together these findings support the concept that intestinal
immunity to live poliovirus may either fail to develop, or
progressively diminish over time in older children and adolescents
leading to an increased likelihood of virus excretion upon oral re-
exposure to live virus. This suggests that in the absence of
additional vaccine doses, mucosal immunity capable of restricting
poliovirus replication in the intestine diminishes after the primary
childhood series, creating an immunological gap in older children,
adolescents and adults.
Age-related deficit in poliovirus vaccine-induced intestinal
immunity
Recent studies have examined the development of intestinal
antibody responses to poliovirus vaccines in somewhat older
children. In a clinical trial conducted in Lithuania, children (ages
1–5 years) who had received up to four doses of IPV in accordance
with the recommended schedule for pediatric immunizations
were challenged with a dose of mOPV2 at study entry51 (Fig. 1).
Despite evidence of strong polio type-specific serum neutralizing
responses, only about one-third of children evaluated for mucosal
antibody responses in stool achieved polio type-2 specific
neutralization titers ≥32 after the first challenge dose of mOPV2.
R.I. Connor et al.
3
Mucosal Immunology
A similar percentage achieved a stool neutralization titer of ≥32
after a second challenge dose. Notably, high titers of virus were
detected in a least one stool sample from a majority of children,
who shed virus after the first or second challenge dose.
This observation in IPV-immunized children is in contrast to
responses seen in vaccine-naïve children, for whom virus
shedding is markedly diminished both in percent shedding and
in mean titer shed with the second dose of the same strain of
OPV52,53. Although these comparisons involve different popula-
tions of differing ages, one conclusion that can be reached is that
initial receipt of IPV in infancy may lead to greater shedding after
an OPV challenge in older children. This has profound program-
matic implications for polio eradication, and may also be an
important insight into the nature of immune control of poliovirus
replication in the intestine. While well-immunized IPV populations
have controlled poliomyelitis and, for the most part poliovirus
transmission, evidence of increased virus shedding in IPV-
immunized older children following oral exposure to live virus
may be significant in terms of potential enhancement of silent
wild-type or VDPV circulation, particularly in geographic areas of
low vaccine coverage.
The relative absence of detectable enteric antibody responses
to live poliovirus in IPV-immunized children as young as 1–5 years
of age is consistent with suboptimal induction of intestinal
immunity in this age range. As compared to findings in IPV-
immunized infants, in which mucosal antibody responses in stool
increased rapidly following OPV challenge17, these results in older
children suggest an age-related defect in enteric mucosal
immunity to poliovirus associated with an increased interval
between immunization and live virus challenge.
Absence of detectable intestinal IgA responses to OPV in
young adults
The possibility that induction of mucosal immunity to poliovirus is less
robust after infancy is further supported by recent findings from a
study of Swedish adults, who had received IPV in childhood as part of
routine immunization programs54,55 (Fig. 1). Not surprisingly, prior to
challenge, subjects had no detectable poliovirus neutralizing activity
in stool and undetectable enteric IgA to all three poliovirus
serotypes55. Following mOPV1 challenge, all subjects experienced
high titered and sustained virus shedding in stool. Unexpectedly,
none developed significant enteric IgA responses to poliovirus during
a 7-week follow-up after challenge. Neutralizing activity against two
other commonly circulating respiratory viruses, influenza A/H1N1 and
respiratory syncytial virus, was detectable in stool from the majority of
the subjects arguing against a more generalized deficit in mucosal
immunity.
Similar results were found in a recent study of Belgian adults, who
had received IPV in childhood and were challenged with a single dose
of a novel OPV type 2 (nOPV2) at study entry56 (Fig. 1). Despite rising
serum neutralization responses, the majority of subjects failed to
develop virus neutralizing titers in stool above the limit of detection
(<4) and those with detectable responses achieved only very low
titers57. These findings are consistent with an earlier report
demonstrating rapid induction of systemic antibody responses but
prolonged virus excretion extending up to 8 weeks after OPV
challenge in elderly Dutch adults, suggesting the absence of mucosal
immunity able to limit virus replication in the intestine58.
Comparison of polio-specific intestinal antibody responses
across age groups
In summarizing data on intestinal immunity from global clinical
trials of bOPV and IPV regimens (Fig. 1) clear distinctions emerge
in the induction of enteric type-specific neutralizing responses to
poliovirus associated with different vaccine regimens and across
age groups (Fig. 2). Two weeks after challenge with mOPV2, the
pattern of neutralizing antibody responses measured in stool
indicates a robust intestinal response to live-attenuated poliovirus
occurs in infants (Fig. 2A–C). Typically strong type-specific enteric
neutralizing responses are seen in infants receiving a primary
series of tOPV (Fig. 2A). Neutralizing titers in stool are also readily
detected in infants receiving a bOPV series (Fig. 2A) or a combined
regimen of bOPV and IPV (Fig. 2A–C). Similar analysis of data from
older children in Lithuania (Fig. 2D) and young adults in Sweden
and Belgium (Fig. 2E, F), however, reveals a striking age-related
diminution in the magnitude of the enteric polio-specific
neutralizing response following OPV challenge.
When considered together, these findings from multiple clinical
trials suggest that, unlike infants, older children and adults may be
less able to mount mucosal IgA responses to poliovirus in the
intestine, despite enteric replication of the virus and strong type-
specific serum antibody boosts. This observation raises questions
as to whether induction of intestinal immunity to poliovirus may
be impaired or absent in adults, a finding that is in marked
contrast to current evidence from infant studies16–18.
Factors affecting levels of enteric IgA to poliovirus measured
in stool
The lack of detectable enteric antibody responses to OPV in older
children and adults may be attributed to a number of possible
factors, including study-related differences in sample size, collec-
tion methods, or changes in the performance of laboratory assays
used to quantify mucosal immunity. In several recent studies,
assessment of enteric responses is substantiated by inclusion of
data from two unique laboratory assays that quantify distinct
immune variables (type-specific mucosal IgA and virus neutraliza-
tion) and that are highly correlated with each other16–18, making it
less likely that variation in laboratory methods accounts for the
observed differences in antibody responses. A decline in intestinal
immunity may also reflect age-related decreases in enteric IgA
produced in older children and adults, which may impact the
overall neutralization potential of stool samples. While total IgA
does decline with age59, it is readily detectable in stool from adult
subjects and correction of polio type-specific responses to reflect
total IgA concentration in stool has not been found to change the
overall findings (Wright et al. unpublished data).
Likewise, it is possible that proteolytic degradation of IgA may
occur during longer stool transit times in older individuals.
However, experiments to evaluate the impact of prolonged
incubation of neutralization-positive samples with stool from
children and adults indicate that this is not a significant
contributing factor (Wright et al. unpublished data). Decreased
enteric IgA in older children and adults may also reflect
physiologic changes that facilitate virus replication in localized
areas of the intestine that are distinct from those typically
associated with antigen-stimulated IgA secretion (e.g., Peyer’s
patches). Alternatively, lower levels of total IgA in stool may stem
from natural age-related involution of the adenoids, tonsils, and
Peyer’s patches—all primary sites of poliovirus replication60.
INDUCTION AND REGULATION OF INTESTINAL IgA responses
to poliovirus
Early development of IgA-mediated mucosal immunity in the
intestine
The underlying question of why infants respond with robust
mucosal antibody responses to OPV in the intestine, and why
these responses wane with age remains unanswered and has clear
implications for the global polio eradication effort. The assump-
tion that IgA-mediated mucosal immunity is critical for control of
enteric poliovirus replication is strongly reinforced by observations
of the striking parallels between the sites of primary poliovirus
replication in epithelial cells of the intestine, and in tissues
associated with the mucosal immune system (e.g., adenoid, tonsil,
and Peyer’s patches)60, and the same anatomic sites being
responsible for induction and expression of mucosal IgA61,62.
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While our current understanding of the maturation of the
mucosal immunologic landscape in infants is incomplete, it is
likely that factors associated with early immune regulation of
polio-specific IgA in infancy play a significant role in determining
the induction and maintenance of mucosal responses to the virus
later in life. Indeed, administration of poliovirus vaccines during
routine pediatric schedules generally coincides with a period of
dynamic immunological development in infancy63,64. Production
of endogenous IgA in the intestine commences during the first
weeks of life and is associated with physiologic tissue maturation,
immune activation, and the development of immunological
tolerance to a wide range of orally ingested antigens63,64.
Importantly, microbial colonization of mucosal sites, which begins
largely at birth, is a driving factor in shaping early innate and adaptive
immune responses to both non-pathogenic and pathogenic organ-
isms65–69. Immune responses to commensal microbes are directed
toward establishing tolerance, limiting inflammation, and maintaining
intestinal homeostasis70,71. However, early exposures to pathogenic
microbes and antigens through infection or immunization concur-
rently shape the immunologic repertoire and establish critical effector
memory responses72.
These responses are orchestrated within the highly adaptive
microenvironment of the intestinal mucosa. Phagocytic macro-
phages and dendritic cells (DC), abundant in the lamina propria,
continuously sample the luminal microbiota and effectively remove
bacteria and pathogens that breach the epithelial barrier73–75.
Microbe-laden DC are restricted to the mucosal compartment by
mesenteric lymph nodes, providing a level of protection against
systemic infiltration of pathogens into the body76.
The interplay of host-microbe mutualism is further refined to
promote distinct adaptive immune responses in systemic and
mucosal compartments. Systemic exposure to a range of microbial
taxa leads to induction of a diverse antibody repertoire dominated
by IgG and designed to prevent lethal microbial sepsis77. In
contrast, mucosal exposure to microbiota elicits a more restricted
response, primarily to microbial surface antigens and character-
ized by a more limited IgA repertoire, which rapidly declines in the
absence of repeated antigenic exposure77. Moreover, while
intestinal memory IgA responses increase after successive antigen
exposures, they do not appear to show the synergistic increase
typical of a systemic prime-boost response78.
This distinction is evident in the observed differences in
antibody responses to systemic or orally delivered poliovirus
vaccines in infants. Notably, subcutaneous or intramuscular
injection of IPV elicits high-titered, serum IgG responses that are
boosted by successive doses, but with little to no generation of
intestinal IgA11,17. Conversely, OPV administered alone or in
combination with IPV stimulates both serum and intestinal
antibody responses, the latter dominated by enteric IgA. Recent
studies demonstrate the influence of the intestinal microbiota on
the magnitude of the enteric IgA antibody response to combined
regimens of IPV and bOPV in infants, suggesting not only the
presence but the composition of the microbiota shape the
adaptive response to poliovirus in the intestine79.
Induction of mucosal IgA is further restricted by a higher
required threshold for antigenic priming as compared to a
systemic response77. In germ-free mice, transitory exposure to a
non-replicating microbe within the intestine requires a dose
a b c
d e f
Fig. 2 Age-related decline in intestinal neutralizing antibody responses to poliovirus following challenge with OPV. Polio type-specific
neutralizing responses were measured in stool following OPV challenge in a series of studies of infants, children, and adults participating in
clinical trials of poliovirus vaccines16–18,51,55,57. Data represent the reverse cumulative distribution of polio type-specific neutralizing titers
measured in stool 2 weeks after OPV challenge in each study. The magnitude of the enteric response is shown as the cumulative probability of
participants achieving a neutralization titer within the specified range. Comparative responses are shown for infants challenged with mOPV2
at 18–28 weeks (A–C); children challenged with mOPV2 at 1–5 years (D) and adults challenged with mOPV1 (E) or nOPV2 (F) at 18–50 years.
Polio type-specific stool neutralization titers were measured as described16–18,51,55,57 and all samples were tested in the same laboratory using
a standardized neutralization assay. Data for each study was analyzed independently to generate reverse cumulative distribution curves.
FIDEC, Fighting Infectious Diseases in Emerging Countries.
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several orders of magnitude higher than that of a systemic
exposure to reshape the antibody repertoire77. It is possible then
that failure to develop a strong intestinal IgA response to OPV
challenge in older children and adults may reflect a sub-threshold
level of antigenic exposure, due to significant microbial competi-
tion in the intestine or the transient nature of antigenic exposure
conferred by a single challenge dose of live, attenuated OPV.
Impact of environmental and host-related factors on intestinal
immunity
Other environmental factors and host-related changes in enteric
immunity may also play a role in modulating IgA responses to
poliovirus vaccines in the intestine. Previous studies have noted
impaired antibody responses to oral polio25–27 and rotavirus80,81
vaccines in developing country settings. Data on enteric immunity
to poliovirus vaccines from several recent clinical trials is uniform
across many countries16–18, although it does not reflect experience
in some of the countries where OPV performance is diminished28.
Parker and colleagues have postulated that interference with the
induction of mucosal immunity to oral vaccines may be due to
altered microbial populations in the gut, nutritional deficiencies or
epigenetic factors that may preferentially affect children from low-
income countries82. Impaired immunogenicity of OPV in children
aged 6–11 months has been shown to correlate with recent
infection with non-polio enteroviruses83. This observation supports
a 2014 meta-analysis showing a consistent negative impact of
concurrent infection with enteropathogens on OPV responses84,
and underscores the potential impact of microbial inference in
reducing induction of polio-specific IgA in the intestine.
Regulation of mucosal IgA by immune cells in the intestine
Cell-mediated immunity to poliovirus in the intestine is much less
well understood than antibody-mediated immunity in part, due to
difficulties in obtaining adequate primary tissues and cells from
this site in young children. Many of the detailed mechanisms of
cell-mediated induction of IgA have been explored in animal
models, and presented in comprehensive reviews61,62,85–88. While
data from human studies is more limited, comparisons with
murine models suggest the salient features of the gut mucosal
immune system, and the functional outcomes needed to respond
and adapt to luminal microbiota and protect against infection, are
conserved between these species89.
In general, induction of antigen-specific IgA within the intestinal
mucosa occurs in highly specialized germinal centers in Peyer’s
patches and in isolated lymphoid follicles. Interaction of B cells with
DC in the subepithelial dome of Peyer’s patches dictates the early
stages of IgA induction90. Subsequent signals from CD4+ T follicular
helper (TFH) and T regulatory (Treg) cells in the germinal centers of
Peyer’s patches control B cell responses in an antigen-specific
manner91,92, and provide signals that promote the switch to IgA-
producing plasma cells85,90. IgA+ plasmablasts enter the circulation
and subsequently home back to the intestine, where they take up
residence in the lamina propria and constitute a primary effector arm
of enteric immunity91.
Transport of antigen-specific IgA from the lamina propria through
the epithelial layer occurs by interaction with polymeric Ig receptors
(pIgR), which mediate transfer of IgA and help stabilize the structure
of the secreted dimeric IgA molecule93. The rate of IgA transport
across the mucosal epithelium is influenced in the lamina propria by
Th17 cells that produce IL-17 in response to co-stimulation with
cytokines94–97. Th17 cells contribute to maintaining intestinal home-
ostasis to commensal microbes via IL-17 induction of pIgR expression,
thereby regulating the rate of IgA secretion into the lumen98.
Cell-mediated suppression of vaccine-induced mucosal
immunity
Maintenance of immune homeostasis in the intestine is critically
dependent on constant adaptation of cell-mediated immune
responses that regulate the quantity and specificity of secreted
IgA91,92,94. It is puzzling then why older children and adults appear
to lose the ability to mount a polio-specific IgA response in the
intestine upon oral challenge with live poliovirus. The loss of
detectable enteric IgA to OPV observed with increasing age raises
questions, as to whether exposure to poliovirus vaccines in infancy
may induce antigen-specific mucosal immune suppression or
tolerance in the gastrointestinal tract99. As the gut is the primary
site of exposure to the majority of foreign antigens early in life,
mechanisms geared towards suppression of excessive immunolo-
gic reactivity and inflammation play a critical role in establishing
and maintaining intestinal homeostasis70.
Several possible immunologic barriers may arise over time in
the intestine to reduce or prevent IgA induction including
inadequate cell-mediated support for IgA production or active
suppression of enteric IgA induced by vaccine antigens. The latter
concept was first demonstrated over 40 years ago in a series of
studies showing that parenteral administration of cholera toxin in
mice induced marked suppression of antigen-specific mucosal IgA
in the intestine100–103. This suppressive effect could be adoptively
transferred by a cellular fraction, presumed to be a suppressor T
cell population103. Whether a similar phenomenon occurs in the
context of parenteral administration of IPV in infancy remains a
hypothesis to explain the lack of polio-specific enteric IgA
responses observed in older children and adults with a history
of childhood IPV.
Tregs with the potential for suppressor activity104 also play a
critical role in IgA induction and maintenance of homeostasis to
commensal microbes in the intestine92,105–107. In mice, depletion
of CD4+ CD25+ Tregs significantly reduces intestinal IgA to
microbial antigens, providing evidence of their essential role in
regulating antibody responses to enteric microbiota92. At home-
ostasis, Tregs establish a tolerogenic state to commensal microbes
by suppressing excessive inflammatory responses to microbial
antigens and preventing gut pathology107.
However, in animal models and adult human studies, Tregs are
also implicated in suppressing B cell responses to certain viral
pathogens and vaccines108–113. In mice infected with Friend virus,
Tregs suppress differentiation of germinal center B cells and plasma
cells, and decrease B cell class switching through downregulation of
CD68 expression, which reduces costimulation by TFH cells112. The
suppressive effects of Tregs on immune responses to viral
pathogens and vaccination are not universal, and distinct effects
can be seen with different pathogens, at different stages of
infection111,114 and after vaccination113, emphasizing the highly
contextual nature of Treg suppressor activity.
Whether suppression of B cell immunity to poliovirus occurs in
the intestine, and whether this is associated with the observed
absence or loss of polio-specific enteric IgA in older children and
adults is not known. In infants an abundance of Tregs home to the
intestine in the first months of life, suggesting these cells play an
essential role in shaping mucosal IgA responses to enteric
microbiota115,116 Studies by Rabe and colleagues have shown
that a higher proportion of circulating Tregs during the first
18 months of life is inversely related to the fraction of T cells that
subsequently express a memory phenotype later in childhood117,
suggesting these cells may further influence the long-term
expression of immunologic memory to vaccine antigens encoun-
tered during infancy117,118.
Modulation of poliovirus immunity in the intestine by vaccine
adjuvants
Human Tregs and Th17 cells in the intestine display a high degree of
plasticity119,120 and can be modulated by co-administration of
vaccine antigens with certain adjuvants. Of interest, the
enterotoxin-based mucosal vaccine antigen LT (R192G/L211A; dmLT)
has been shown to induce strong antigen-specific Th17 responses
and increase mucosal IgA to co-mixed antigens following parenteral
R.I. Connor et al.
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or oral immunization121–123. Co-administration of dmLT with a dose-
sparing amount of IPV in mice has been shown to promote polio-
specific intestinal IgA and upregulate expression of the intestinal
homing receptor α4β7 on trafficking T cells122. Clinical trials of dmLT
co-administered with IPV in adults are ongoing and will yield
valuable information on the impact of targeted modulation of
cellular responses for induction of long-lived polio-specific mucosal
IgA and virus neutralizing responses in the intestine.
Contribution of tissue-resident memory T cells to poliovirus
intestinal immunity
In the absence of detectable enteric IgA to poliovirus in older
children and adults, control of poliovirus replication in the intestine
may rely in part on tissue resident memory T (TRM) cell populations.
TRM are found in abundance in the epithelium of barrier sites such
as the skin and mucosae, where they serve as sentinels to rapidly
activate broad localized immunity124–127. TRM play a central role in
antiviral immunity through cytokine-mediated recruitment of both
innate and adaptive immune cells, and by direct lysis of virally
infected cells128. Unlike circulating CD8+ T-cells, TRM in the
gastrointestinal tract appear to be maintained independently of
cognate antigen for long periods and may serve to limit the
duration of virus shedding129. Whether these cells participate in
controlling poliovirus replication in the intestine is not currently
known. However, ongoing studies of intestinal immunity in adults
with prior history of IPV or OPV in childhood will shed light on the
impact of early exposure to poliovirus antigens on the develop-
ment of long-term cell-mediated memory responses able to
control virus shedding later in life.
CONCLUSIONS
The impact of early childhood immunization with live and
inactivated polio vaccines during a period of dynamic immuno-
logic development is likely to play a significant role in establishing
functional cell-mediated memory responses capable of stimulat-
ing mucosal IgA and restricting virus replication in the intestine.
Current observations of an age-related decline in enteric mucosal
IgA and virus neutralizing responses to OPV, associated with
sustained virus shedding, raise important questions as to the
nature of immune regulation of poliovirus replication in the
intestine and have clear implications for global eradication efforts.
Promising new data is now emerging on the safety and
immunogenicity of novel type 2 oral poliovirus vaccines (nOPV2)
with improved genetic stability after intestinal passage130,131.
These studies will undoubtedly further shape our understanding
of the induction and regulation of mucosal immunity to poliovirus.
With an increasing number of vaccine-derived poliovirus out-
breaks occurring globally, deployment of nOPV2 and ongoing
clinical development of nOPV types 1 and 3 will provide critical
new tools to help mitigate the risk of further seeding of vaccine-
derived virulent strains into vulnerable populations, and to reduce
the number of cases of polio associated with these outbreaks.
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